Shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $52.83.
PTHS has been the subject of a number of research reports. Oppenheimer lowered their price target on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a report on Friday, August 14th. Alliance Global Partners restated a “buy” rating on shares of Pelthos Therapeutics in a research note on Monday, October 26th. Zacks Research raised shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 4th. Finally, Lake Street Capital lowered their price target on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 12th.
Read Our Latest Research Report on PTHS
Institutional Inflows and Outflows
A hedge fund recently raised its position in Pelthos Therapeutics stock. Knott David M Jr boosted its holdings in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) by 9.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,073 shares of the company’s stock after buying an additional 1,792 shares during the period. Knott David M Jr owned approximately 0.63% of Pelthos Therapeutics worth $443,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 77.96% of the company’s stock.
Pelthos Therapeutics Price Performance
Pelthos Therapeutics stock opened at $9.39 on Thursday. The stock has a market cap of $35.96 million, a price-to-earnings ratio of -0.43 and a beta of 3.41. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. Pelthos Therapeutics has a 1 year low of $8.72 and a 1 year high of $37.40. The firm has a 50-day moving average of $18.84 and a two-hundred day moving average of $23.62.
Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The company had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. On average, research analysts forecast that Pelthos Therapeutics will post -15.22 earnings per share for the current year.
About Pelthos Therapeutics
We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).
Further Reading
- Five stocks we like better than Pelthos Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Pelthos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pelthos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
